0000950170-23-047530.txt : 20230911 0000950170-23-047530.hdr.sgml : 20230911 20230911174220 ACCESSION NUMBER: 0000950170-23-047530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230907 FILED AS OF DATE: 20230911 DATE AS OF CHANGE: 20230911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brady Todd C CENTRAL INDEX KEY: 0001579179 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 231248583 MAIL ADDRESS: STREET 1: C/O EVOKE PHARMA, INC. STREET 2: 505 LOMAS SANTA FE DRIVE CITY: SOLANA BEACH STATE: CA ZIP: 92075 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 ownership.xml 4 X0508 4 2023-09-07 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001579179 Brady Todd C C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 true true false false President and CEO false Common Stock 2023-09-07 4 M false 192084 0.552 A 1647369 D Common Stock 2023-09-07 4 M false 32953 0.552 A 1680322 D Common Stock 2023-09-07 4 M false 48021 0.552 A 1728343 D Common Stock 2023-09-07 4 F false 73807 7.22 D 1654536 D Stock Option (right to buy) 0.552 2023-09-07 4 M false 192084 0.00 D 2023-09-07 Common Stock 192084 0 D Stock Option (right to buy) 0.552 2023-09-07 4 M false 32953 0.00 D 2023-09-07 Common Stock 32953 0 D Stock Option (right to buy) 0.552 2023-09-07 4 M false 48021 0.00 D 2023-09-07 Common Stock 48021 0 D Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the exercise of the stock options. The stock option is fully vested. /s/ Todd C. Brady 2023-09-11